cancer pain
Conditions
Interventions
Group A:hydromorphone intravenous PCA
Group B:Oxycodone oral
Sponsors
People's Hospictal of Jiangxi Province
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The subjects volunteered and signed the informed consent of the trial; 2. Tissue or pathology diagnosed as cancer; 3. Aged >= 18 years and = 4 in the past 24 hours; 5. Patients who had not received radiation therapy within 7 days prior to randomization and trial; 6. Patients with no history of allergy to narcotic drugs; 9. Patients with ECOG-ps <= 3.
Exclusion criteria
Exclusion criteria: 1. The patient was diagnosed with non cancerous pain or unexplained pain; 2. Paralytic intestinal obstruction; 3. Patients with metastatic brain cancer with cerebral symptoms; 4. Patients with abnormal and clinically significant laboratory results, such as creatinine >= 2 times of the upper limit of normal value, ALT or AST >= 2.5 times of the upper limit of normal value (liver metastasis or primary liver cancer >= 5 times of the upper limit of normal value), or child C grade of liver function; 5. Cognition impairment ; 6. Participate in drug trials (including this drug) within 1 month prior to the trial; 7. Diseases and conditions that other researchers consider ineligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success rate of titration on the first one;Time of successful titration; | — |
Secondary
| Measure | Time frame |
|---|---|
| Success rate of titration on the second?the third day;Symptoms Improved Conditions (ESAS Scale);Satisfaction with pain control;Pain score of transition of hydromorphone to oral oxycodone after intravenous PCA titration and the proportion of successful conversion; | — |
Countries
China
Contacts
Public ContactYao Weirong
People's Hospictal of Jiangxi Province
Outcome results
None listed